165 related articles for article (PubMed ID: 10470244)
1. Tumour markers in prostate cancer: EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2799-801. PubMed ID: 10470244
[No Abstract] [Full Text] [Related]
2. Tumour markers in germ cell cancer: EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2795-8. PubMed ID: 10470243
[No Abstract] [Full Text] [Related]
3. Tumour markers in breast cancer--EGTM recommendations. European Group on Tumor Markers.
Anticancer Res; 1999; 19(4A):2803-5. PubMed ID: 10470245
[No Abstract] [Full Text] [Related]
4. Tumour markers in lung cancer: EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2817-9. PubMed ID: 10470248
[No Abstract] [Full Text] [Related]
5. Tumour markers in gastrointestinal cancers--EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2811-5. PubMed ID: 10470247
[No Abstract] [Full Text] [Related]
6. Quality requirements and control: EGTM recommendations. European Group on Tumour Markers.
Anticancer Res; 1999; 19(4A):2791-4. PubMed ID: 10470242
[No Abstract] [Full Text] [Related]
7. Tumour markers in gynaecological cancers--EGTM recommendations. European Group on Tumor Markers.
Anticancer Res; 1999; 19(4A):2807-10. PubMed ID: 10470246
[No Abstract] [Full Text] [Related]
8. [Screening for prostate cancer: results from the first screening round in the French population of the ERSPC trial].
Richard F
Prog Urol; 2009 Jul; 19(7):499-500. PubMed ID: 19559381
[No Abstract] [Full Text] [Related]
9. Application of prostate-specific antigen in prostate cancer.
Liang SL
MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
[No Abstract] [Full Text] [Related]
10. PSA velocity and prostate cancer detection: the absence of evidence is not the evidence of absence.
Perrin P
Eur Urol; 2006 Mar; 49(3):418-9. PubMed ID: 16459016
[No Abstract] [Full Text] [Related]
11. [Mass screening for prostate cancer will have to wait. The scientific basis insufficient, more efficient markers necessary].
Damber JE
Lakartidningen; 2003 Sep; 100(38):2916-8, 2921. PubMed ID: 14558209
[No Abstract] [Full Text] [Related]
12. [PSA based screening for prostatic cancer].
Johansen TE
Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2612-4. PubMed ID: 19023357
[No Abstract] [Full Text] [Related]
13. Early detection of prostate cancer: is PSA a reliable option?
Okihara K; Babaian RJ
Tex Med; 2001 Feb; 97(2):59-62. PubMed ID: 11233061
[TBL] [Abstract][Full Text] [Related]
14. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
Höltl W; Lunglmayr G
Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
[No Abstract] [Full Text] [Related]
15. Best screening tests for prostate cancer.
Moul JW
West J Med; 1998 Aug; 169(2):109-10. PubMed ID: 9735692
[No Abstract] [Full Text] [Related]
16. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
Hamilton RJ; Platz EA; Freedland SJ
J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
[No Abstract] [Full Text] [Related]
17. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
18. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
Bratt O; Björk T
Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
[No Abstract] [Full Text] [Related]
19. [Based on current knowledge the introduction of the PSA screening for prostatic cancer is unethical].
Krantz I; Sachs L; Ahlberg BM; Nordin P; Nilstun T
Lakartidningen; 2005 Sep 5-11; 102(36):2498-500. PubMed ID: 16196436
[No Abstract] [Full Text] [Related]
20. Is an improved PSA screening test in sight?
Savage L
J Natl Cancer Inst; 2007 Oct; 99(20):1503-4. PubMed ID: 17925529
[No Abstract] [Full Text] [Related]
[Next] [New Search]
